Results 131 to 140 of about 65,592 (243)

Detection of MSI signals from peripheral blood for monitoring response to immune checkpoint blockade therapy in patients with advanced microsatellite‐unstable gastrointestinal cancers: A pilot study

International Journal of Cancer, Volume 158, Issue 12, Page 3312-3323, 15 June 2026.
What's new? A substantial proportion of patients with microsatellite‐unstable gastrointestinal adenocarcinomas do not benefit from immunotherapy. This study demonstrates that microsatellite instability can be reliably detected in plasma‐derived extracellular vesicle DNA from patients with microsatellite‐unstable gastrointestinal cancers.
Aysel Ahadova, Lena Bohaumilitzky, Thomas Walle, Joscha A. Kraske, Mirjam Tariverdian, Ulrike Ganserer‐Schmitt, Ingrid Hausser‐Siller, Vera Fuchs, Nina Nelius, Gizem Mehtap Erisen, Johannes Gebert, Albrecht Stenzinger, Dirk Jäger, Magnus von Knebel Doeberitz, Georg Martin Haag, Elena Busch, Matthias Kloor   +16 more
wiley   +1 more source

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yoshihide Ueda, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +53 more
wiley   +1 more source

Advances and Future Perspectives for the Management of Non‐Small Cell Lung Cancer in Australia: A Narrative Review

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 333-350, June 2026.
Lung cancer remains Australia's leading cause of cancer death. With new screening and evolving therapies, equitable access and workforce readiness are essential. This review discusses current and emerging treatments for NSCLC in Australia, clinical trials underway, and future directions in delivering optimal, accessible care nationwide.
Lauren Julia Brown, Graham Meredith, Bo Gao, Pei Ding, Harriet Gee, Inês Pires da Silva, Adnan Nagrial, Eric Hau   +7 more
wiley   +1 more source

Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review

International Journal of Dermatology, EarlyView.
Niyoosha Yoosefi, Adrian Tabari, Jeffrey Donovan   +2 more
wiley   +1 more source

Personalized Cancer Vaccines in the Clinical Trial Pipeline

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 3, Page 362-368, June 2026.
ABSTRACT Aim To present an overview of personalized cancer vaccines currently undergoing clinical development, aiming to enhance awareness and promote collaboration among academic, commercial researchers, and non‐profit communities. Methods A dataset of 78 clinical trials for personalized cancer vaccines was generated using ClinicalTrials.gov database ...
Liudmila Iamukova, Elena Alferova
wiley   +1 more source

Profile of ipilimumab and its role in the treatment of metastatic melanoma

Drug Design, Development and Therapy, 2011
Sapna P Patel, Scott E WoodmanMelanoma Medical Oncology Department, University of Texas, MD Anderson Cancer Center, Houston, TX, USAAbstract: Melanoma is an immunogenic cancer.
Patel SP, Woodman SE
doaj  

Immunotherapy in advanced gastroesophageal cancers: A meta‐analysis of sex‐based outcomes in overall survival

International Journal of Cancer, Volume 158, Issue 10, Page 2697-2708, 15 May 2026.
What's New? Immune checkpoint inhibitors (ICIs) improve survival in advanced gastroesophageal cancer (GEC), but their benefits may differ by sex. Little is known, however about the impact of sex‐related immune differences on ICI efficacy. In this meta‐analysis, sex‐specific outcomes of ICI therapy were evaluated in advanced GEC, encompassing both ...
Michael Masetti, Fausto Petrelli, Filippo Pietrantonio, Sylvie Lorenzen, Alberto Giovanni Leone   +4 more
wiley   +1 more source

Alveolar Soft Part Sarcoma in Pediatric and Young Adult Patients: A Report From the Children's Oncology Group Study ARST0332

Pediatric Blood &Cancer, Volume 73, Issue 5, May 2026.
ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane, Wei Xue, Amira Qumseya, Thomas Scharschmidt, Kathryn R. Tringale, Oscar Lopez Nunez, Jiaqi Hu, Donald A. Barkauskas, Rajkumar Venkatramani, Sheri L. Spunt, Aaron R. Weiss, Noah C. Federman   +11 more
wiley   +1 more source

Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma

Clinical, Cosmetic and Investigational Dermatology, 2013
Giulio Tosti, Emilia Cocorocchio, Elisabetta PennacchioliDivisione Melanomi e Sarcomi, Istituto Europeo di Oncologia, Milano, ItalyAbstract: Approaches aimed at enhancement of the tumor specific response have provided proof for the rationale of ...
Tosti G, Cocorocchio E, Pennacchioli E
doaj  

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, Volume 13, Issue 25, 4 May 2026.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source